Liver and Brain Connection: How Liver Health Impacts Cognitive Function
At first glance, the liver and brain may seem unrelated organs. One filters toxins; the other processes thoughts. But modern […]
Fibronostics Joins Experts in Liver Health at THASL 2025 Bangkok
On June 11-13, Fibronostics had the privilege of participating in the THASL 2025 Annual Conference, hosted by the Thai Association
LIVERFASt (L-FAST) Identifies Advanced (F3F4, AF) and Clinically Significant Fibrosis (F2-F4, CSF) in MASLD Patients
In a biopsy-validated cohort of MASLD patients (n=399, with 235 T2D), combining LIVERFASt with Fibroscan correctly identified 95% of F3–F4
The Utility of Non-Invasive Tests (NITs) – LIVERFASt, FIB4 and VCTE (Fibroscan) in MASH Patients
This publication evaluates the real-world use of non-invasive tests (LIVERFASt, FIB-4, and VCTE) in monitoring MASH patients undergoing resmetirom therapy.
Association between Psoriasis Severity & Steatosis Measured by AI-based Algorithm (LIVERFAStTM)
This publication explores the relationship between psoriasis severity and liver steatosis using the AI-based LIVERFASt tool. Patients with more severe
Combination of LIVERSTAT (LST) and Fibroscan (LSM) Outperforms FIB-4 and LSM for MASLD Advanced Fibrosis
Combining LIVERSTAT with Liver Stiffness Measurement (LSM) more effectively identifies advanced liver fibrosis (F3F4) in patients with MASLD, particularly those
Combination of LIVERfASt (LF) & Liver Stiffness Measurement (LSM) in patients with type 2 diabetes (T2D)
Combining LIVERFASt with Liver Stiffness Measurement (LSM) is more effective than FIB-4 & LSM for identifying advanced liver fibrosis in
LIVERFASt: Non-Invasive Liver Assessment for Chronic Hepatitis B & Diabetes
This publication introduces LIVERFASt, a non-invasive biomarker for predicting liver steatosis and fibrosis in patients with chronic Hepatitis B and
Fatty Liver Explained: Causes, Prevention, and Early Detection
What Is Fatty Liver Disease? Fatty liver disease, now widely known as MASLD (Metabolic dysfunction-associated steatotic liver disease), is a
Fibronostics to Exhibit at THASL 2025 Annual Conference in Bangkok
Fibronostics is pleased to announce its participation in the THASL 2025 Annual Conference, hosted by the Thai Association for the Study of the